Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Survival: 10.7 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Houston, Texas
Hospital: The University of Texas MD Anderson Cancer Center
Journal: Link
Date: 9/2013

This phase 2 study involved 45 patients with diffuse large B-cell lymphoma, transformed large cell lymphoma, or grade 3 follicular lymphoma. The median patient age was 66 years and 62% were male.

Patients were treated with the biologic therapy agent rituximab (monoclonal antibody for CD20 that directs the immune system to kill cancer cells) and the immunomodulatory (biologic) agent called lenalidomide that interferes with cancer cell growth.

There was one death due to “natural causes” during the study that may have been due to treatment. Grade 4 neutropenia, thrombocytopenia, and leukopenia were also reported.

The median overall survival was 10.7 months.

Some of the authors have received funding from Celgene Corporation.

Correspondence: Dr. M Wang; email:

E-mail to a Friend Email Physician More Information